The aim of this study was to evaluate the efficiency and safety of single-agent bevacizumab therapy for recurrent @entity463 ( @entity463 ). We identified @entity1 with histologically confirmed @entity463 and World Health Organization Grade III @entity11 who were previously treated with @entity2903 plus radiotherapy and received 10  mg/kg bevacizumab intravenous infusion every 2  weeks until disease progression for recurrent disease. A total 24 @entity1 included to this study. Twenty-two @entity1 had @entity463 , and two @entity1 had WHO grade III @entity11 . No complete response was observed, five @entity1 (20.8  %) had partial response, nine @entity1 (37.5  %) had stable diseases, and ten @entity1 (41.7  %) had progressive diseases. The overall response rate was 20.8  %. The 6-month PFS rate (PFS6) and median PFS were determined as 37.5  % and 4.1  months, respectively. Median @entity3012 was 6.4  months. Performance status of 17 (70.8  %) @entity1 was improved following bevacizumab regimen. Univariate analysis showed that improvement @entity159 ( @entity159 ) following bevacizumab therapy was a significant predictor of both PFS (p  <  0.001) and @entity3012 (p  <  0.020). Bevacizumab-related adverse effects were observed in 13 (54.1  %) @entity1 . Grade 3-4 @entity137 was observed in 4 (16.6  %) @entity1 . Therapy interruptions were experienced in two @entity1 due to adverse effects. Single-agent bevacizumab is an effective and safe treatment alternative in recurrent @entity463 . @entity159 following bevacizumab therapy was a significant predictor of both PFS and @entity3012 .

Single-agent bevacizumab is an effective treatment in recurrent XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity11 :: ('MESH:D005910', 'Disease') :: ['glioma'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma multiforme', 'GBM', 'glioblastoma'] @entity159 :: ('MESH:D013226', 'Disease') :: ['IPS', 'in performance status']
@entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']
